For more information, follow the links below to the study listings on www.clinicaltrials.gov.
ALOPECIA AREATA
CTP-543
Medical professionals may also email us at AAclinicaltrial_inquiries@concertpharma.com for more information about CTP-543 study participation.
THRIVE-AA1: A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Evaluating the efficacy and safety of CTP-543 in adult patients with moderate to severe alopecia areata.
Status: Recruiting
https://clinicaltrials.gov/ct2/show/NCT04518995
Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Evaluating the safety and efficacy of CTP-543 in adult patients with chronic, moderate to severe alopecia areata.
Status: Completed
https://clinicaltrials.gov/ct2/show/NCT03137381
Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
Evaluating the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata
Status: Completed
https://clinicaltrials.gov/ct2/show/NCT03941548
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
Evaluating the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata
Status: Completed
https://clinicaltrials.gov/ct2/show/NCT03811912
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Evaluating long-term safety of CTP-543 and to assessing long-term effects of CTP-543 in adult patients with chronic, moderate-to-severe alopecia areata who completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial.
Status: Active, Not Recruiting
https://clinicaltrials.gov/ct2/show/NCT03898479
SCHIZOPHRENIA
CTP-692
Medical professionals may also email us at CNSclinicaltrial_inquiries@concertpharma.com for more information about CTP-692 study participation.
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
Evaluating the safety and efficacy of CTP-692 in patients with schizophrenia on stable antipsychotic medication.
Status: Active, Not Recruiting
https://clinicaltrials.gov/ct2/show/NCT04158687
Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers
Assessing in healthy male and female subjects the safety and pharmacokinetic (PK) profiles of 3 dose levels of CTP-692 following 7 days of dosing.
Status: Completed
https://clinicaltrials.gov/ct2/show/NCT03880253
Expanded Access/Compassionate Use
Concert is committed to developing innovative medicines for autoimmune and CNS disorders.
Participation in our clinical trials plays a vital role in helping develop new medicines. While we do not currently offer investigational therapies outside of our clinical trials, you and your physician may determine that enrolling in a trial may be an option for you. For more information about Concert’s ongoing clinical trial programs, please reference the trials listed above.
